日本の将来を考えるにあたり、国民の日々の安心が守られ、必要な革新的医薬品が国民に遅滞なく届くよう、国民皆保険制度を維持しつつ、戦略産業の観点からもイノベーションを推進し、国力を高めることが重要です。医薬品に焦点を当て、日本における課題と議論を整理し、薬価制度、薬事制度といった具体的な取り組みについて考察します。
Education
- MS, Medical Sciences, Graduate School of Medicine, University of Tokyo
- BA, Pharmaceutical Sciences, University of Tokyo
Motoko Ishikawa joined Boston Consulting Group in 2015. She is a core member of the firm’s Health Care practice. Motoko works mainly with clients in the pharmaceutical and medical device industries. She has worked on numerous projects including covering R&D and innovation strategies, medium- and long-term corporate strategies, organizational reform, and market access strategies.
Prior to joining BCG, Motoko worked as a reviewer at the Pharmaceuticals and Medical Devices Agency.